Determination of a new calcium antagonist in human plasma by liquid extraction enrichment and HPLC with UV detection

Flaminio, L.; Malavasi, B.; Ripamonti, M.; Ascalone, V.

doi:10.1007/bf02263888

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The plasma samples were vortexed for 2 minutes and centrifuged at 10,000 rpm for 15 minutes. The resulting upper organic layer was collected, and 50µL of the sample was injected into the UHPLC-HESI-MS n for analysis[9][10][11][12].…”

mentioning

confidence: 99%

Bioanalytical Method Development and Validation of Doxorubicin and Lapatinib in Rat Plasma Using UHPLC-HESI-MSn

Shaik,

Srika,

Sharma

et al. 2023

Preprint

View full text Add to dashboard Cite

A simple, selective, and robust method was developed to simultaneously detect doxorubicin and lapatinib in rat plasma using UHPLC-HESI-MSn based on a protein precipitation technique for extracting analytes from rat plasma. Chromatographic separation was accomplished on Waters symmetry® C18 3.5µm (4.6×75mm) column using 0.1% acetic acid in water and 0.1% acetic acid in acetonitrile as eluents followed by HESI-MSn detection. Quantifying doxorubicin and lapatinib using curcumin as an internal standard was carried out using a single reaction monitoring mode of the tandem mass spectrometer. The method is valid over the concentration range of 0.75 ng-1200 ng. This UHPLC-HESI-MSn method was fully validated based on other parameters like selectivity, matrix effect, recovery and stability. This validated method is straightforward, robust and can be clinically applicable.

show abstract

mentioning

confidence: 99%

Bioanalytical Method Development and Validation of Doxorubicin and Lapatinib in Rat Plasma Using UHPLC-HESI-MSn

Shaik,

Srika,

Sharma

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Bioanalytical Method Development and Validation of Doxorubicin and Lapatinib in Rat Plasma Using UHPLC-HESI-LTQ-MS

Moinuddin,

Srikanth,

Sharma

et al. 2023

Journal of Chromatographic Science

View full text Add to dashboard Cite

Cancer is considered a silent killer. The complexity of cancer makes it earn that title. So far there are only a few approaches to treat cancer. Among them, chemotherapy is considered the best approach. Many chemotherapeutical compounds are commercially available in the market. Among them, doxorubicin (DOX) and lapatinib (LAP) are considered blockbuster molecules. However, DOX suffers from poor bioavailability and exhibits cardiotoxicity. Interestingly, a fixed dose combination of DOX and LAP significantly decreases the cardiotoxic effect of DOX. To enhance the oral bioavailability of DOX and to avail the synergistic effect of LAP, many formulations have been made. To quantify both compounds in any formulation or biological matrix, an Liquid chromatography-Mass Spectrometry (LC-MS) method is required. In this present study, a simple and rapid Ultra High-Performance Liquid Chromatography - Heated Electron Spray Ionization - Mass Spectrometry (UHPLC-HESI-MS) bioanalytical method was developed. The developed method was validated as per the regulatory guidelines. The validated bioanalytical method had a lower limit of quantification of 0.75 ng. A simple protein precipitation technique was optimized to extract the compounds from the rat plasma. All the validation parameters were found to be within the limits as per the regulatory guidelines. A novel and rapid analytical method was successfully developed and validated. This developed method can be used to quantify the DOX and LAP in any formulation and biological matrix.

show abstract

Determination of a new calcium antagonist in human plasma by liquid extraction enrichment and HPLC with UV detection

Cited by 2 publications

References 6 publications

Bioanalytical Method Development and Validation of Doxorubicin and Lapatinib in Rat Plasma Using UHPLC-HESI-MSn

Bioanalytical Method Development and Validation of Doxorubicin and Lapatinib in Rat Plasma Using UHPLC-HESI-MSn

Bioanalytical Method Development and Validation of Doxorubicin and Lapatinib in Rat Plasma Using UHPLC-HESI-LTQ-MS

Contact Info

Product

Resources

About